RemeGen: Two Self-Developed Drug Franchises and an Export Licensing Engine, With the A-Share Already Pricing a Cleaner Future Than the Filings Justify

Company vertical history and financial review

Origins and listing path

RemeGen was incorporated in the PRC on 2008-07-04 and spent its first decade building what the company itself describes as full-industry-chain biologics capabilities. The founding structure mattered. Scientifically, the company was shaped by Dr. Fang Jianmin, a biologist trained at Dalhousie University who did postdoctoral cancer research at Harvard Medical School and Boston Children’s Hospital and is credited by the company as the inventor of telitacicept and disitamab vedotin. Industrially and organizationally, it was shaped by Wang Weidong, who would become chairman and who has long sat inside the controlling-shareholder and concert-party structure. That pairing of scientific inventor and industrial organizer goes a long way toward explaining why RemeGen did not become just another licensing shell. It built discovery, development, manufacturing, and commercialization under one roof in Yantai.

The company converted into a joint-stock company on 2020-05-12, then took the Hong Kong market route first. The November 2020 HKEX float raised about HKD3.99 billion at HKD52.10 per share, before any over-allotment exercise. That offering sold capital markets a classic pre-profit China biotech pitch: differentiated biologics, self-owned intellectual property, and two core assets aimed at large unmet need. The second leg came on 2022-03-31, when RemeGen completed its STAR Market A-share IPO at RMB48.00 per share, with net proceeds of about RMB2.506 billion. The A-share offering was not financial engineering. The stated use of proceeds was what one would expect from a rising biologics platform: industrialization, core-product development, additional antibody R&D, and working capital.

That sequencing, Hong Kong first and Shanghai later, also shaped how investors came to understand the company. Hong Kong initially saw RemeGen as a Chapter 18A science story. Shanghai later saw it as a strategic domestic innovative-drug asset with a nationally important technology stack. The result is still visible today in pricing. The Hong Kong line has remained closer to a global biotech framework, discounting dilution, execution risk, and cash conversion. The A-share line has more often capitalized national-biotech scarcity and domestic enthusiasm for de-risked innovation. The business is one company; the market narratives are not.

Stages and key nodes

The first stage ran from founding through 2020. This was platform construction: antibody engineering, fusion proteins, ADC know-how, manufacturing capability, and enough preclinical and clinical substance to justify a major biotech IPO. The company’s own retrospective description of the period is telling. It emphasizes integrated development capability since inception, not just a single molecule. That matters because RemeGen’s eventual business model turned out not to be “one lucky drug.” It turned into something broader: one autoimmune franchise, one ADC franchise, and a growing ability to license adjacent assets.

The second stage was 2021 through 2022, when science finally became product. Telitacicept received conditional China approval for systemic lupus erythematosus in March 2021. Disitamab vedotin received approval in gastric cancer in June 2021 and a later urothelial-cancer approval in December 2021. National reimbursement followed quickly for key labels. RemeGen’s revenue base shifted from licensing-heavy and lumpy to product-led and recurring. The mistake investors often made in this stage was to treat “approved” as equivalent to “scaled.” Commercial infrastructure still had to be built, doctors had to be educated, hospitals had to list the drugs, and additional indications still mattered enormously to volume.

The third stage, 2023 through 2024, was the hard middle. Revenue kept growing, but not fast enough to absorb the company’s appetite for R&D and commercial investment. Revenue rose from RMB1.08 billion in 2023 to RMB1.71 billion in 2024, yet R&D still ran at RMB1.31 billion and RMB1.54 billion, while selling expenses climbed from RMB775 million to RMB949 million. Loss before tax remained deep at roughly RMB1.51 billion in 2023 and RMB1.47 billion in 2024. This was the period when the share price and narrative were most punitive. Investors stopped paying for “pipeline breadth” and started demanding evidence that any China biotech could become self-funding without endless dilution. RemeGen responded by going back to capital markets, placing 19 million new H shares in May 2025 at HKD42.44 for gross proceeds around HKD806 million and net proceeds around HKD796 million. Even the better assets still needed cash.

The fourth stage began in 2025 and is still underway. This is the real transition. Telitacicept won gMG approval in May 2025. Disitamab vedotin posted strong first-line urothelial data, had the filing accepted in July 2025, and later picked up a breast-cancer approval in March 2026. Telitacicept then added Sjögren’s disease and IgA nephropathy on 2026-06-08. At the same time, the company changed the economics of its own pipeline. Vor Bio licensed ex-Greater China telitacicept in 2025; Santen took RC28-E for China ophthalmology; AbbVie took ex-Greater China rights to RC148 in 2026. Those deals did two things at once. They brought in cash, and they cut the amount of capital RemeGen itself would need to commit to every geography and indication. That is why 2025 looks like an inflection year in the financials: the business got better and the accounting got help, both at once.

One key node deserves special attention because it still affects the stock today: the Vor Bio warrants. The annual report shows that the group held warrants valued at US$80 million issued by Vor Bio as part of the 2025 telitacicept licensing agreement, and the 2025 cash-flow statement shows RMB640.7 million of fair-value changes in financial assets at fair value through profit or loss. The 2026 first-quarter report then shows another RMB361.2 million of fair-value gain from changes in fair value. So part of the “profitability transition” is a function of monetizable biotech-paper economics, not only medicine sold to hospitals. That does not make the income fake. It does make it less repeatable than a pure product margin.

Another key node is the 2025 H-share placement. In a weaker view of the company, that placement reads as dilution forced by cash burn. In the stronger view, it was opportunistic bridge capital raised just before the company could demonstrate a step-change in approvals and business-development relevance. With hindsight, it was neither fatal nor irrelevant. It diluted shareholders, but it also reduced financing risk at a fragile point in the industry cycle and gave the company room to push telitacicept into gMG, Sjögren’s disease, and nephrology. The stock’s later rerating suggests the market eventually treated that capital raise as part of a transition rather than a sign of distress.

Financial vertical review and price history

The last five full years tell a clear story of scale before quality. Revenue was RMB1.42 billion in 2021, RMB768 million in 2022, RMB1.08 billion in 2023, RMB1.71 billion in 2024, and RMB3.24 billion in 2025. The odd dip from 2021 to 2022 reflects the lumpy mix of licensing and early commercialization that often distorts young biopharma P&Ls. By 2025 the structure was much more commercially anchored: product-sales revenue alone was RMB2.307 billion. Gross profit rose sharply with that transition, reaching RMB2.816 billion in 2025 from RMB1.367 billion in 2024. But the company spent heavily to get there. Selling expenses were still RMB1.11 billion in 2025 and R&D was RMB1.22 billion, even after a substantial year-on-year reduction from RMB1.54 billion in 2024.

The earnings trend is best read in two layers. At the statutory layer, RemeGen moved from pre-tax losses of roughly RMB999 million in 2022, RMB1.51 billion in 2023, and RMB1.47 billion in 2024 to pre-tax profit of RMB710 million in 2025, with profit attributable to ordinary equity holders of RMB709.7 million. At the underlying layer, the bridge includes a very large non-cash valuation component. The 2025 cash-flow statement shows RMB640.7 million of fair-value gain on financial assets through profit or loss, and operating cash flow was only RMB52.3 million. The company did improve the real business: it collected more from product sales, grew gross profit, and cut R&D intensity. It just did not yet generate earnings of the same quality as the statutory bottom line suggests.

Cash conversion is the most important financial warning light. For 2025, operating cash flow was RMB52.3 million versus RMB709.7 million of attributable profit, a conversion ratio of about 0.07x. Capital expenditure on property, plant and equipment and intangibles was about RMB200.0 million, so free cash flow remained negative even after the reported profit inflection. The same pattern appears in the first quarter of 2026. Operating revenue rose 24.8% year on year to RMB656.2 million and operating cash flow turned positive at RMB11.3 million against a negative RMB188.3 million a year earlier, but adjusted net profit after non-recurring items was still a RMB35.0 million loss, while headline attributable net profit was a RMB328.0 million profit because non-recurring gains, above all fair-value changes on financial assets and warrants, totaled roughly RMB363.0 million. A company can grow into clean earnings from here. The filings show it has not done so yet.

The balance sheet is no longer fragile, though it is not the fortress balance sheet implied by the most enthusiastic reading of the stock. At 2025 year-end the company had RMB1.155 billion of cash and cash equivalents, RMB1.216 billion of financial assets held at fair value through profit or loss, and interest-bearing bank borrowings of about RMB2.159 billion. By the end of the first quarter of 2026, cash and bank balances were RMB1.122 billion, financial assets held for trading were RMB1.624 billion, and borrowings were roughly RMB1.730 billion. Count trading financial assets as quasi-cash and liquidity looks comfortable; insist on cash alone and leverage still matters. The right reading sits between those poles: the company is not facing immediate funding stress, but part of that comfort comes from business-development monetization and financial assets, not from a fully self-funding operating model.

The price history tells the same story in market language. The Hong Kong line was born into the late-stage China biotech enthusiasm of 2020, then suffered the same derating that hit most revenue-light or cash-burning peers. The A-share line arrived in 2022 at RMB48.00 and later benefited from the domestic market’s willingness to capitalize local innovative-drug champions at richer multiples. By June 2026, the two lines had split dramatically. Using directly verifiable June 24 closes, the A share sat near RMB117.55 while the H share, translated into renminbi, sat near RMB59.81. That gap is not a commentary on assay quality or hospital demand. It is a commentary on capital-market habitat. The market has moved RemeGen from being priced as a binary biotech to being priced, at least onshore, as a scarce commercial winner. The business has earned some re-rating. The A-share multiple expansion has gone much further than the improvement in recurring earnings quality.

Business model, moat, and governance

Revenue machine and operating leverage

RemeGen’s real business machine has three layers. The first layer is domestic product sales. In 2025, product-sales revenue was RMB2.307 billion, up 35.8% year on year, driven by telitacicept in autoimmune disease and disitamab vedotin in oncology. Hospital coverage also widened materially: the annual report says that by 2025 year-end telitacicept had entered more than 1,200 hospitals and disitamab vedotin more than 1,050. Those numbers matter more than a general “commercial stage” label because biologics in China do not scale by approval alone; they scale through reimbursement, tendering, physician education, and hospital listing.

The second layer is indication expansion. Telitacicept started in SLE, then broadened into RA and gMG, and has now moved into Sjögren’s disease and IgA nephropathy. Disitamab vedotin has been widening from gastric cancer and later-line urothelial use into breast cancer and potentially first-line urothelial cancer. This label expansion is where the operating leverage comes from, not side decoration. The company does not need to build a new commercial organization from scratch for every adjacent indication. It needs to deepen physician reach, broaden department coverage, and improve reimbursement utilization around brands it already sells. That is why approvals matter not just clinically but mechanically for margin structure.

The third layer is licensing and partnering. Here RemeGen increasingly resembles a hybrid of a domestic commercial biopharma and an export-oriented biotech licensor. The Vor Bio, Santen, and AbbVie transactions show three versions of the same logic. If a molecule or modality can be monetized outside RemeGen’s core geography or outside its immediate commercial focus, management is willing to trade part of the long tail for cash upfront, milestone streams, and royalties. In a capital-hungry industry, that is part of the business model rather than a minor tactic. It lowers self-funded R&D burden, reduces execution complexity, and turns unbooked pipeline optionality into balance-sheet-supporting assets. It also introduces earnings lumpiness. That trade-off is central to how the stock should be analyzed.

Cost structure shows why scale alone does not immediately create clean earnings. Selling expenses reached RMB1.11 billion in 2025, up from RMB948.8 million in 2024, while R&D fell to RMB1.22 billion from RMB1.54 billion. Administrative expense stayed relatively contained at RMB362.4 million. This mix tells you that RemeGen’s hardest-to-cut costs are still the ones most intrinsic to an innovative-drug franchise: field-force spending to drive adoption and scientific spending to keep the next indications moving. The company does have operating leverage. It just has not yet reached the point where recurring product gross profit comfortably outruns the combined cost of commercial effort and pipeline maintenance.

Moat

RemeGen has a real moat in molecule ownership. Telitacicept and disitamab vedotin are not in-licensed follow-ons with thin economic rights. They are internally developed assets with meaningful intellectual-property and platform significance for the company. Fang Jianmin is credited by the company as inventor of both. That matters because the best economics in biotech sit with originators that can choose whether to self-commercialize, out-license, or combine the two. RemeGen still controls those choices.

It also has a real moat in integrated capability. Since inception, the company has built end-to-end biologics development functions. That has allowed it to move from discovery to approval to manufacturing to sales inside China, then to partner out assets abroad from a position of ownership rather than scientific dependence. Plenty of China biotechs can generate interesting phase II data. Far fewer can launch two different biologic modalities, widen labels, and simultaneously sign global licensing deals. That does not make the moat unassailable. It does mean the company has capabilities that are harder to copy than a single clinical readout.

The weakest part of the moat is competition at the disease level. Telitacicept’s mechanism gives it differentiation, but not monopoly. In autoimmune disease it competes for physician mindshare and future guideline positioning against belimumab, FcRn approaches, BAFF-pathway competitors, and global assets such as Novartis’ ianalumab in Sjögren’s disease and argenx’s VYVGART franchise in myasthenia gravis. In ADCs, disitamab vedotin competes in a far more brutal field that includes Daiichi Sankyo’s HER2 franchise, Pfizer/Seagen’s broader ADC ecosystem, and comparator regimens like Padcev plus pembrolizumab in urothelial cancer. RemeGen’s moat is therefore strongest at the company level, where asset ownership and integrated execution compound, and weaker at the individual-indication level, where competition remains intense.

Management and governance

Management deserves serious credit for scientific and strategic execution. The company turned two self-owned biologics into approved products, extended both across multiple indications, and persuaded sophisticated external partners to pay meaningful upfront money for ex-China rights. Those are hard things to fake. Delivery has been strong enough that by 2026 the market no longer treats RemeGen as a marginal biotech player.

Governance is more mixed. The annual report shows an unusually broad concert-party controlling structure: Wang Weidong, Fang Jianmin, other executives and directors, and affiliated entities act in concert on major decisions. It also discloses connected relationships involving RC Pharma and MabPlex. None of this amounts to scandal. The annual report says the group had no material breach of relevant laws and regulations in 2025, and Ernst & Young remains auditor. The structure still deserves a governance discount: control is concentrated, related-party linkages exist, and ordinary shareholders are buying into a founder-led ecosystem rather than a simple one-share-one-influence corporate setup.

The family dimension also became more visible over time. The 2025 annual report references share awards involving Fang Michelle Yi, identified there as the daughter of Fang Jianmin, and a June 2026 filing shows her elected or re-elected as an executive director. Family continuity is not automatically bad, but it lowers the margin for complacency on governance. For now I would describe management credibility as good on science, decent on capital markets, and merely average on minority-shareholder alignment.

Industry, cycle, and horizontal competitor analysis

Industry and cycle

RemeGen sits inside two fast-moving but very different industries: autoimmune biologics and ADC oncology. Both are still growth markets, but the source of growth differs. In autoimmune disease, growth comes from diagnosis, biologic penetration, label expansion, and the willingness of payers and physicians to move earlier in the disease course once efficacy and safety become convincing. In ADCs, growth comes from targeting, combination regimens, biomarker segmentation, and the current industry belief that conjugates can keep moving earlier in treatment lines. RemeGen is unusual because it has one foot in each arena. That is a strategic advantage. It also forces investors to track two different competitive clocks.

The cycle that matters most here is not the macro cycle. It is the policy-and-liquidity cycle. China innovative-drug companies live and die by reimbursement access, regulatory speed, data credibility, and their ability to finance long development arcs. The company’s own history shows this clearly. The period of widest losses coincided with a harsher financing backdrop for biotech, while the rerating began when approvals, hospital penetration, and licensing transactions reduced dependence on public markets. Technology iteration is the second key cycle. A drug that looks differentiated in 2024 can become merely one option in 2028 if a rival modality shifts the standard of care.

Regulation is therefore a core economic variable, not a compliance footnote. China approvals and NRDL inclusion have already shaped both core products. The annual report notes that telitacicept’s SLE label was renewed in the NRDL in 2023 and 2025 and that gMG entered the NRDL in December 2025; it also notes that both disitamab vedotin labels were renewed at the end of 2025. Each renewal protects access. Each incremental label increases commercial density. At the same time, ex-China progress depends on partners, foreign trial execution, and overseas regulators. The market should value RemeGen’s science exportability, but it should not assume regulatory symmetry across geographies.

How the competitive set has sorted itself

The closest listed China peer in spirit is Sichuan Kelun-Biotech. Kelun-Biotech is also an ADC-centered China innovator, it has already monetized platform quality through large licensing deals, and the market currently values it at roughly HKD98.5 billion. Kelun has become a platform ADC house with broad strategic optionality. RemeGen has become more balanced: a two-franchise company with a commercial autoimmune engine alongside ADC oncology. Kelun looks stronger if one believes the next decade belongs overwhelmingly to conjugates. RemeGen looks better diversified if one wants both immune and oncology shots on goal.

Akeso is not a direct molecule peer, but it is a useful capital-markets peer. The market currently capitalizes Akeso at roughly HKD80 billion. Investors use Akeso as the poster child for what happens when a China innovator crosses from being dismissed as another domestic biotech to being treated as globally relevant. RemeGen is earlier in that journey. The comparison matters because it shows what the market pays for perceived platform legitimacy and ex-China optionality. It also shows the danger of paying up too early. Akeso’s valuation, like RemeGen’s A-share line, contains a large narrative component.

argenx is the best commercial benchmark for what a world-class autoimmune franchise can become. Its market capitalization sits above US$56 billion. RemeGen is nowhere near that level of global commercial execution, but argenx shows the value that markets assign when an autoimmune asset becomes a repeated-use, multi-indication, cash-generative platform rather than a single approval. This is the most important long-duration bull reference for telitacicept, particularly in myasthenia gravis.

Vera Therapeutics is a mechanism-level comparator for the kidney-disease side of telitacicept’s story because of atacicept and IgA nephropathy. With a market cap around US$2.7 billion to US$3.2 billion despite lacking RemeGen’s China commercial base, Vera highlights two things. First, ex-China investors are willing to pay meaningful value for BAFF/APRIL-pathway kidney optionality alone. Second, RemeGen has more moving parts than U.S. biotech investors usually get in one package, which can both help and hurt valuation clarity. It helps because there are several ways to win. It hurts because markets struggle to cleanly separate recurring value from option value.

At the disease level, customers choose each company for different reasons. Hospitals and physicians choose RemeGen’s telitacicept because it is approved, reimbursed, and increasingly broad in label; they do not buy it because they have sworn allegiance to a platform. Oncologists choose disitamab vedotin where HER2 expression, line of therapy, local label support, and combination data justify it. By contrast, argenx sells a global autoimmune brand with stronger international guideline presence, and Kelun sells an ADC platform narrative that investors award with strategic scarcity. RemeGen’s niche is not “the best company in autoimmune” or “the best company in ADC.” It is the rare China company that has one viable franchise in each and has already shown it can monetize them in more than one way.

Ecological niche

RemeGen is best described as a challenger with two profit pools under construction. It takes share from the old profit pool of symptomatic or less-targeted autoimmune care by offering a dual-target biologic across multiple B-cell-driven diseases. In oncology it tries to take share from less precise chemotherapy regimens and from rival targeted regimens in HER2-expressing tumors. The company becomes stronger if policy continues to reward innovative-drug reimbursement, if China physicians continue to adopt locally developed biologics, and if partners pull overseas assets forward. It becomes weaker if the next treatment standards are set by faster global competitors before RemeGen’s data can travel.

Current fundamentals and valuation analysis

What is happening now

The most recent filings show a business still improving, but not in a straight line. First-quarter 2026 operating revenue was RMB656.2 million, up 24.8% year on year. Cash receipts from sales of goods and provision of services rose to RMB765.8 million from RMB475.1 million. R&D spending fell 36.2% year on year to RMB209.9 million, which management directly linked to technology licensing of products. Those are all constructive operating signs.

The problem is that headline profitability remains heavily distorted by non-recurring valuation effects. First-quarter attributable net profit was RMB328.0 million, but adjusted attributable net profit after non-recurring items was negative RMB35.0 million. The report discloses RMB364.0 million of gains tied to changes in fair value and disposal of financial assets, and explicitly says the swing in total profits came from three factors: higher product-sales revenue, lower R&D due to licensing, and changes in warrant fair value. That disclosure does most of the interpretive work for an investor. The quarter was better. It was not yet a clean proof that recurring operations alone justify the current A-share valuation.

The event flow since the annual report has still been undeniably strong. On 2026-06-08 the company announced that the NMPA approved telitacicept for Sjögren’s syndrome and conditionally approved it for IgA nephropathy. Earlier in 2026, disitamab vedotin was approved for HER2-positive breast cancer with liver metastasis, and the annual-results announcement notes CDE breakthrough-therapy designation for the combination regimen in first-line HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma. The market has good reasons to think the next 12 months can bring more label depth, not less.

What the market is trading

The stock is mainly trading a re-rating from “burning cash” to “commercial and licensable.” Real fundamentals support part of that rerating. Product sales are growing, hospital coverage is broadening, approvals are arriving in adjacent indications, and overseas business-development deals are large enough to change financing risk. The market narrative is that RemeGen has crossed the difficult part of the biotech valley.

The overheated part of that narrative is the assumption that statutory profit now equals a mature earnings base. It does not. In 2025, the cash-flow statement shows fair-value changes of RMB640.7 million against profit before tax of RMB710.4 million. In first-quarter 2026, non-recurring gains of roughly RMB363.0 million explain the vast majority of reported attributable net profit. This does not invalidate the company. It does mean the market, especially in Shanghai, is increasingly paying for a future earnings mix that has not yet arrived in recurring form.

The largest present distortion is the A/H gap. On the latest directly verifiable coordinated closes, the A-share line values the company at about RMB66.4 billion, while the H-share line implies about RMB33.8 billion. That makes the A-share line the real object under debate. Look only at 09995.HK and RemeGen appears like a high-risk but still arguable growth name. Look at 688331.SHG and it looks like a good company that the local market has already pre-paid for.

Valuation analysis

The first discipline is cash-flow passthrough. Over the most recent full year, operating cash flow was RMB52.3 million against RMB709.7 million of attributable profit, or about 7% conversion. The cash-flow statement also shows depreciation and amortization of roughly RMB320.3 million and capex of about RMB200.0 million in 2025. I assume roughly RMB80 million to RMB100 million of that capex is maintenance and the rest growth, because the company is commercializing, still building, and running biologics manufacturing capacity. Under that assumption, owner earnings in 2025 were far below headline earnings and likely only modestly positive at best after stripping out fair-value gains. That is well more than a 30% gap from headline profit, so the valuation below leans on owner-earnings logic and sum-of-the-parts rather than the statutory P/E.

On the A-share line, the headline numbers are already rich. Using the 2026-06-24 A-share close of RMB117.55 and the 2025 diluted/basic EPS of RMB1.29 from the annual report, the stock trades at roughly 91 times trailing earnings. Using the 2025 revenue base of RMB3.24 billion and the current A-line market value of roughly RMB66.4 billion, the stock trades at about 20.5 times trailing sales. On the H-line, the equivalent price-to-sales ratio is closer to 10.4 times. Those two numbers describe the whole problem in one glance. Investors are not debating whether RemeGen is good. They are debating how much of its future should be capitalized today, and the two markets are giving radically different answers.

For absolute valuation, the right method is a blend: value the current commercial franchise, add a risk-adjusted NPV for pipeline and licensing streams, then adjust for net financial assets. I do not think a simple DCF on reported earnings is the right tool, because reported earnings still contain too much fair-value noise. I also do not think a pure pipeline rNPV is enough, because by now the domestic commercial revenue base is too large to be treated as speculative. So the framework below uses a sum-of-the-parts approach.

The valuation framework rests on three explicit assumptions. First, telitacicept and disitamab vedotin together remain the core value drivers through 2030, with telitacicept likely overtaking RC48 as the more durable franchise if kidney and Sjögren’s uptake is real. Second, business-development cash flows from Vor Bio, Santen, and AbbVie retain value but should be risk-discounted heavily because milestone timing is uncertain. Third, the appropriate discount rate for a China innovative-drug company with this mix of commercial and pipeline risk is still high, in the low-double-digit range, not a mature large-cap pharma rate. Those assumptions are deliberately less generous than the mood currently embedded in the A-share line.

The scenario table below values the current commercial franchise separately from pipeline and licensing. It uses fully diluted current issued shares of about 564.48 million as disclosed in the first-quarter filing. The scenarios are intentionally simple. Their job is not to predict 2030 exactly. Their job is to show what the current price already assumes.

The business reading behind those numbers is straightforward. RemeGen can justify a substantial equity value even on a skeptical view, because it now owns two approved platforms and meaningful licensing optionality. What it cannot justify, on present evidence, is an A-share market value that already asks investors to pay above the top end of a reasonable optimistic range. The H-share line is a different conversation. The A-share line demands faith that recurring earnings quality will quickly catch up to approvals, and that competition will not narrow pricing power before then.

The expectation gap is therefore sharp. The market cares most about four things at the next major checkpoints: how quickly Sjögren’s disease and IgA nephropathy convert into prescription volume; whether first-line urothelial approval arrives and how broad the eventual label is; whether ex-China partners continue to advance programs rather than merely hold options; and whether reported profit increasingly comes from recurring operations instead of fair-value marks. If those data points come in strong, the fundamental case can grow into the valuation. If not, the risk is not merely a missed quarter. It is a multiple reset toward the H-share line’s logic.

On margin of safety, the answer is strict. The current A-share price is well above the value implied by the conservative scenario, so the margin of safety is zero. The most fragile assumption in the base case is clean earnings normalization, not peak sales. If underlying recurring earnings only reach 70% of my base assumption, the base-case fair value falls from roughly RMB60–76 per share toward the mid-RMB50s to upper-RMB60s. If earnings were flat for the next three years and the share price simply de-rated toward a more normal commercial-biopharma framework, returns from the current A-share price would likely trail the opportunity cost of holding safer assets. This is a classic good-company-bad-price setup on the Shanghai line. Margin-of-safety sufficiency verdict: none.

Risk analysis

The first permanent-loss risk is competitive replacement in kidney and neuromuscular disease. Probability is medium; impact is high. Telitacicept’s recent approvals have widened its addressable market, but they also move the product into larger and more contested disease areas where global competitors are serious. The transmission path is simple: if physician adoption in IgA nephropathy or gMG is slower than implied by current excitement, RemeGen loses the operating leverage that the market is pricing into future margins, and the multiple contracts before sales can catch up. The observable indicators are early rollout speed, NRDL utilization, and whether overseas partners continue investing behind these programs.

The second permanent-loss risk is that RC48’s first-line urothelial promise proves commercially narrower than its trial data suggest. Probability is medium; impact is high. The phase III data were strong, but oncology standards move quickly and physician behavior depends on label detail, biomarker definitions, competing regimens, and reimbursement. The risk path is revenue disappointment followed by lower confidence in RC48 as a multi-line platform, which would hit both product-sales assumptions and the perceived value of overseas development. The observable indicators are final label details, early uptake after approval, and whether external developers continue expanding RC48 in multiple indications.

The third risk is earnings-quality disappointment. Probability is high; impact is high. This is not a hypothetical future concern. The filings already show it. In 2025, fair-value gains on financial assets were enormous relative to profit, and in first-quarter 2026 adjusted profit remained negative. If the market starts valuing RemeGen on recurring owner earnings rather than statutory profit, the A-share line is exposed to a sharp rerating even if the business itself does not implode. The indicator is simple: net profit after non-recurring items and operating cash flow need to trend decisively upward for several quarters.

The fourth risk is capital-markets convergence between the A and H lines. Probability is medium; impact is high for A-share holders and much lower for H-share holders. The business does not need to deteriorate for this risk to materialize. It only requires domestic liquidity or sentiment to cool. A 96%-plus A/H premium is large enough that part of the rerating can occur through line convergence alone. The observable indicators are the size of the premium, southbound and northbound sentiment, and whether new A-share buyers remain willing to pay a markedly different valuation for the same economics.

The fifth risk is governance slippage in a founder-controlled system. Probability is low to medium; impact is medium. There is no evidence in the annual report of major accounting or regulatory failure, but the company does have a concert-party control structure, connected relationships with affiliated entities, and visible family presence in the governance picture. In benign markets, investors ignore such structures. In rough markets, they discount them quickly. The indicator here is not one quarter’s revenue. It is any pattern of related-party dependence, unusual capital allocation, or governance decisions that favor insiders over outside holders.

Catalysts and tracking indicators

The positive catalysts are clear. More telitacicept label conversion after the June 2026 approvals, first-line urothelial approval for RC48 in China, visible milestone receipts from partners, and a sequence of quarters in which adjusted profit and operating cash flow rise together would all strengthen the case materially. The negative catalysts are just as clear: any slowdown in prescription conversion after new approvals, any delay or narrower-than-expected label on RC48, a reversal in fair-value gains masking weak core economics, or a simple compression of the A/H premium.

The tracking dashboard below is designed for this specific company rather than for biotech names in general.

Why these matter is straightforward. Product-sales growth tells you whether approvals are becoming volume. Adjusted profit tells you whether the business is becoming cleaner. Operating cash flow tells you whether the cleaner business is also becoming real. R&D intensity tells you whether management is buying growth efficiently or simply spending because it can. For RemeGen the A/H premium is part of the valuation thesis itself, not just a trading artifact. Hospital coverage is the best simple proxy for commercial depth in China. Regulatory progress for RC48 and partner progress for ex-China assets are the two biggest bridges between today’s revenue base and tomorrow’s optionality.

Cross-synthesis summary

The single most important thing RemeGen has proven across its whole journey is that it can originate and carry biologics far enough to become economically relevant. That sounds obvious, but in China biotech it is not. Many companies proved they could raise money. Fewer proved they could produce one approved product. Fewer still proved they could produce two self-owned commercial assets in distinct modalities, keep extending labels, and then monetize adjacent science through overseas licensing. That is the core capability the company has earned, and it did not come mainly from luck. It came from a combination of scientific ownership, platform continuity, and a willingness to stay integrated instead of becoming a perpetual licensor too early.

At the same time, the past success should not be misread. RemeGen’s earlier market success was not the result of clean financial execution. It was the result of technology promise during a period when public markets funded promise generously. What changed in 2025 was not only that product sales rose. It was that licensing and asset monetization started to bridge the gap between a broad science platform and the cash demands of turning that platform into a durable company. That is a good transition. It is still a transition. The conditions that produced the worst losses, namely high R&D intensity, heavy commercialization spend, and a biotech market less willing to fund long-duration narratives, have not disappeared. They have just become easier to carry.

Horizontally, RemeGen’s advantage is not simplistic product superiority across every indication. It is the shape of the portfolio. Kelun-Biotech is a purer ADC bet. Akeso is a broader China innovation rerating story. argenx is a much more mature autoimmune commercialization benchmark. Vera is a cleaner mechanism-specific kidney-disease comparator. RemeGen’s real edge is that it has already built one autoimmune growth engine and one oncology growth engine and can monetize assets outside both through partnering. Its main weakness is that this portfolio shape makes earnings harder to read. A simple recurring-pharma multiple undervalues the pipeline, but a simple pipeline multiple overvalues the quality of current earnings.

That distinction leads directly to the stock verdict. The present A-share valuation is not mainly rewarding past success. It is pre-spending future success. The market is pricing RemeGen as if the shift from reported profitability to recurring profitability were largely complete, as if new labels will convert smoothly into volume, as if RC48’s front-line opportunities will commercialize without major friction, and as if the A/H gap can remain structurally enormous. The filings do not support that collective leap. They support a better company than the market saw in 2024. They do not support a fully cleaned-up earnings story in 2026.

What the market is most likely misjudging now is the timing of earnings quality, not the scientific value of telitacicept or RC48. That is the variable sitting under every other debate. If adjusted profits turn sustainably positive, operating cash flow strengthens, and new indications accelerate product sales without another lurch upward in cost intensity, the company can grow into a much higher intrinsic value over time. If instead 2026 continues to show a large gap between recurring operations and headline earnings, then the A-share multiple becomes extremely vulnerable even if the company keeps winning approvals. In other words, the most important variable for the next year is profit quality, not raw news flow. Over three years, the key variable becomes how much China autoimmune and oncology label breadth turns into durable franchise depth. Over five years, the question becomes whether RemeGen is still mainly a China commercializer with side licensing, or a true global-originator platform with recurring royalty economics.

The company becomes a meaningfully better investment under two conditions. The first is business improvement: at least two to three consecutive quarters in which adjusted profit and operating cash flow stay positive while product-sales growth remains above 20%. The second is price discipline: either the A/H premium compresses substantially or the A-share price falls into a range that gives investors room for execution slippage. Conversely, the original judgment should be re-examined if new indications fail to convert, if partner momentum stalls, or if management begins to depend on more external funding despite all the recent licensing validation. A good company can still be a poor stock. That is the center of this case.

Bull and bear reasons

Bull reasons:

• Telitacicept has moved from one approved autoimmune indication to five in China by June 2026, adding Sjögren’s disease and IgA nephropathy on top of SLE, RA, and gMG, which materially enlarges the addressable commercial base.
• Disitamab vedotin’s first-line urothelial phase III data were strong enough to support a credible standard-of-care debate, with ORR of 76.1% and median PFS of 13.1 months versus 6.5 months for chemotherapy.
• The company has already shown it can monetize science globally, with Vor Bio, Santen, and AbbVie all paying meaningful upfront economics and potential milestones.
• 2025 product-sales revenue reached RMB2.307 billion and total revenue RMB3.242 billion, showing that RemeGen is not dependent on a single one-off licensing line for sales relevance.
• Balance-sheet pressure has eased because cash, trading financial assets, and partner economics now offset much more of the funding burden than in 2023–2024.

Bear reasons:

• 2025 reported profit quality was weak: operating cash flow was only RMB52.3 million against RMB709.7 million of attributable profit, with RMB640.7 million of fair-value gains in the cash-flow bridge.
• First-quarter 2026 headline profit of RMB328.0 million still masked an adjusted loss of RMB35.0 million after non-recurring items.
• The A-share line traded at roughly a 96.5% premium to the H-share line on the latest directly verifiable coordinated closes, making valuation risk largely a market-structure risk as well as a business risk.
• Both core franchises are entering more competitive settings, with global autoimmune and ADC competitors still capable of reducing pricing power and narrowing label-based advantages.
• Governance deserves a discount because control sits within a concert-party structure and related-party linkages remain part of the ecosystem.

Pre-mortem

A plausible three-year failure script looks like this. By 2027, the initial excitement from Sjögren’s disease and IgA nephropathy approvals has not translated into the prescription curve bulls expected. Telitacicept remains a good product, but uptake in nephrology is slower, hospital coverage grows less than hoped, and global progress under Vor Bio slips against management’s desired timelines. At the same time, the market stops capitalizing fair-value gains as if they were recurring earnings. Adjusted profit remains patchy, operating cash flow is volatile, and the A-share line compresses from a narrative-rich framework toward the H-share line’s logic. In that script, a move from RMB117.55 toward the RMB55–70 range is not extreme. It is simply the result of recurring economics failing to catch up to price.

A second script centers on RC48. The first-line urothelial cancer data remain clinically impressive, but label wording, reimbursement, and competing regimens narrow real-world commercial impact. RC48’s contribution then disappoints just as the market had begun to treat it as the second leg of a highly profitable two-engine company. At the same time, the Shanghai line loses some domestic momentum and the A/H premium compresses. You then get both earnings disappointment and multiple compression. The share price does not need any scandal to halve. It only needs the market to decide that RemeGen is still a transition company, not yet a finished compounder.

Final research conclusion

RemeGen is a better business than the bear case from 2024 allowed for. It now has two real commercial products, wider label breadth, visible hospital penetration, and a licensing record that proves outside counterparties see real value in its science. This company has passed the credibility test. What it has not yet passed is the earnings-quality test. The filings still show too much dependence on fair-value and other non-recurring effects relative to the level of market confidence embedded in the A-share line.

That is why the stock verdict depends on which line you anchor to. In Hong Kong, RemeGen looks like a risky but understandable growth vehicle whose value still partly rests on future execution. In Shanghai, investors are already paying for a much cleaner future than the current owner-earnings profile warrants. I think the company is worth owning only once price and earnings quality speak the same language. Today they do not, at least on 688331.SHG. What would change my mind is not another headline approval by itself. It would be a run of quarters in which adjusted profit turns sustainably positive, operating cash flow improves meaningfully, and new indications show real prescription conversion. Until then, the A-share line looks like a good company at the wrong price.

【Company-profile scores】

• Fundamental quality: medium
• Growth: high
• Moat: medium
• Financial soundness: medium
• Management credibility: medium
• Valuation attractiveness: low
• Risk level: high
• Suitable investor type: not suitable for the general investor

【Investment rating】

• Rating: Avoid
• One-line thesis: Strong science and real approvals are already over-capitalized in the A-share line while recurring earnings quality remains unproven.
• Three price signals:
  • 【Ideal Buy Price】36–40 CNY
  • Basis: at least a 20% margin of safety below the value implied by the conservative scenario, which places fair value around RMB46–52 per share.
  • Acceptable hold price: 59–79 CNY
  • Clearly overvalued price: 110+ CNY
• Current-price classification: clearly overvalued
• Whether to wait for a better price: yes. A buy would require both a lower A-share price and cleaner recurring earnings; the practical opportunity cost of waiting is missing near-term newsflow, but that trade-off is acceptable at the current valuation.
• Target holding horizon: 3–5 years
• Expected annualized return: conservative about -27% CAGR, base about -16% CAGR, optimistic about -5% CAGR from the current A-share price over a three-year normalization horizon.
• Max-loss risk: 45%–55%, triggered by a mix of slower-than-expected commercialization of new indications, persistent adjusted losses, and A/H valuation compression.
• Reassessment-trigger signals:
  • if adjusted net profit remains negative through late 2026 despite new telitacicept labels
  • if operating cash flow turns negative again on a rolling 12-month basis
  • if RC48 first-line urothelial approval is delayed materially or arrives with a commercially narrower label
  • if partner programs under Vor Bio or AbbVie visibly lose momentum
  • if the A/H premium remains extreme without accompanying improvement in recurring profit quality

【Valuation Range】

• current: 117.55 (close as of 2026-06-24)
• bear (conservative · ideal buy zone): [36, 40]
• base (fair · acceptable hold zone): [59, 79]
• bull (optimistic · above the clearly-overvalued line): [110, 125]

Key data tables

The financial table below compiles the most important vertical metrics from the company’s annual reports and the 2026 first-quarter report.

The table shows the central paradox. Revenue is scaling fast, R&D intensity is easing, and liquidity is improving. But the bridge from revenue growth to clean cash earnings is still incomplete. That gap is manageable for the business and dangerous for the multiple.

Research uncertainties

• The company does not disclose product-level 2025 revenue detail for telitacicept and disitamab vedotin in the primary filings I could verify directly, so the franchise-level valuation necessarily relies on total product-sales revenue plus indication judgments, not a perfectly segmented sales model.
• Precise daily close data for both lines on 2026-06-25 were not directly available from one uniform primary exchange dataset inside the accessible sources, so I used the latest directly verifiable coordinated 2026-06-24 closes and current issued share count from the 2026 first-quarter filing.
• The timing of milestone recognition from Vor Bio, Santen, and AbbVie is inherently uncertain; that is why the valuation discounts those streams heavily rather than capitalizing the headline deal values.
• Ex-China competitive dynamics in gMG, nephrology, and HER2-targeted oncology could change faster than domestic label progress, especially if global standards of care move before RemeGen’s partners complete development.
• The right maintenance-capex estimate for a young, expanding biologics manufacturer is judgmental; I used a conservative assumption rather than treating all capex as optional growth spending.

Sources

Primary sources used most heavily in this report:

• RemeGen annual report 2025, published 2026-04-29.
• RemeGen annual report 2024, published 2025-04-29.
• RemeGen 2026 first-quarter report, published 2026-04-29.
• RemeGen 2025 annual results announcement, published 2026-03-27.
• RemeGen / HKEX announcement on telitacicept approvals for Sjögren’s disease and IgA nephropathy, 2026-06-08.
• Reuters on AbbVie’s January 2026 RC148 collaboration with RemeGen.
• Vor Bio press release and HKEX documentation on the June 2025 telitacicept ex-Greater China deal.
• Santen press release on RC28-E licensing economics, 2025-08-19.
• ESMO coverage of RC48-C016 phase III first-line urothelial results.
• HKEX and SSE listing/IPO materials and company listing announcements for the 2020 HK IPO and 2022 STAR IPO.

Other tickers mentioned

• 6990.HK: Sichuan Kelun-Biotech, the closest China ADC platform and licensing peer discussed in the horizontal analysis.
• 09926.HK: Akeso, a useful China innovative-drug rerating peer for capital-markets comparison.
• ABBV.US: AbbVie, RemeGen’s ex-Greater China licensee for RC148 and an important validator of platform value.
• ARGX.US: argenx, the best global commercialization benchmark for what a scaled autoimmune franchise can be worth.
• VERA.US: Vera Therapeutics, a mechanism-level comparator for BAFF/APRIL-pathway kidney-disease optionality.
• PFE.US: Pfizer, relevant because Seagen’s RC48 relationship now sits within Pfizer.
• 4568.TSE: Daiichi Sankyo, a global HER2-ADC benchmark for the oncology side of the competitive landscape.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.